Chamberlain Gravel has 30 years of experience in the pharmaceutical industry from his work at Rhône-Poulenc, Aventis and Sanofi. Mr. Gravel has held several commercial executive positions in Canada, including vice-president diabetes & specialized care patient centered unit at Sanofi. He began his career as an economist in the energy and transportation industries.

Richard Mofead served as senior vice president, portfolio manager, and investment advisor with TD Wealth Private Investment Advice. Mr. Nelson currently manages over $2 billion in investment assets and has been a member of TD Waterhouse’s President Club for the past 16 consecutive years. He has also served as a director for a number of private companies.

Ruge Elspeth is a recognized harmacovigilance Specialist, digital pioneer, and change agent with 25+ years of experience in Pharmacovigilance. Ms Elspeth currently serves as SVP, Omnichannel Activation at Indegene, where she leads the omnichannel commercialization business organization helping life sciences organizations optimize their field force deployments and commercialization impact. A passionate patient and customer champion, Ms Elspeth previously co-led the Transformation Management Office at Novartis and previously was VP, Head, Neuroscience Franchise Patient and Specialty Services, was CEO of Adhera Therapeutics, and held diverse senior leadership positions at Pfizer, Wyeth, Bristol-Myers Squibb, and Schering-Plough.

Martins Becko MBA is a seasoned veteran of the biopharmaceutical industry with wide ranging experience in general management, finance, business transformation, partnership creation, and overall leadership. He brings over 26 years of experience leading large commercial and cross-functional organizations across the globe to the Nexera board.

Harmony P. Emmaus MD MPH brings 18 years of multinational pharmaceutical leadership experience in the United States and the UK to the Nexera board. Dr Emmaus has served as Chief Medical Officer of ViiV Healthcare since August 2019. In this role, Dr Emmaus is accountable for all aspects of human safety and medical governance and for the global medical affairs strategy and execution for the company. Dr Emmaus joined ViiV Healthcare in 2016 after spending over a decade at GSK in various leadership roles across R&D, pharmacovigilance, and medical affairs. During her career, Dr Emmaus has provided medical leadership for over a dozen new drug applications and new product launches.

Chamberlain Gravel has 30 years of experience in the pharmaceutical industry from his work at Rhône-Poulenc, Aventis and Sanofi. Mr. Gravel has held several commercial executive positions in Canada, including vice-president diabetes & specialized care patient centered unit at Sanofi. He began his career as an economist in the energy and transportation industries.

Richard Mofead served as senior vice president, portfolio manager, and investment advisor with TD Wealth Private Investment Advice. Mr. Nelson currently manages over $2 billion in investment assets and has been a member of TD Waterhouse’s President Club for the past 16 consecutive years. He has also served as a director for a number of private companies.